智通财经APP获悉，凯莱英(06821)午后涨近6%，截至发稿，涨5.49%，报97.1港元，成交额4458.26万港元。
消息面上，凯莱英与天津经开区管委会签署合作备忘录，在天津经开区持续扩建化学大分子创新药CDMO研发生产基地，预计投资规模达20亿元人民币，该项目将进一步提升公司在多肽、寡核苷酸（TIDES）等新分子类型的CDMO一站式服务能力，更好满足全球合作伙伴的多元需求。
公开数据显示，2025年凯莱英化学大分子CDMO板块实现营业收入10.28亿元，同比增长123.72%，成为公司增长最为迅速的业务单元。公司预计26年多肽PPQ项目将达4个且多肽固相合成产能将从25年底的4.5万升增至26年底的6.9万升。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.